Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies

Background: CTLA-4 was the first immune checkpoint targeted for cancer therapy and the first target validated by the FDA (Food and Drug Administration) after approval of the anti-CTLA-4 antibody, Ipilimumab. However, clinical response rates to anti-CTLA-4 antibodies are lower while the rates of immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Peng, Xiong, Xinxin, Rolfo, Christian, Du, Xuexiang, Zhang, Yan, Yang, Han, Russo, Alessandro, Devenport, Martin, Zhou, Penghui, Liu, Yang, Zheng, Pan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073233/
https://www.ncbi.nlm.nih.gov/pubmed/31991588
http://dx.doi.org/10.3390/cancers12020284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073233/
https://www.ncbi.nlm.nih.gov/pubmed/31991588
http://dx.doi.org/10.3390/cancers12020284

Ejemplares similares